Pharma

sponsor
Become a Member Today!
Register
Email:


Password:

Remember me
Forgot your Password?
Invite Code?
Article ID

Most Viewed Abstracts



Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Angiotech Pharmaceuticals, Inc. announced that its corporate partner, Boston Scientific Corporation, hasreleased comprehensive data from the TAXUS ATLAS clinical program, a series of global, prospective, single–arm trials evaluating the TAXUS Liberte Paclitaxel–Eluting Stent System in a variety of lesions and patient groups. Three–year results from the TAXUS ATLAS Small Vessel and Long Lesion Trials continue to show significant advantages for the newer TAXUS Liberté Stent when compared to the first–generation TAXUS Express Stent.

Today in Drug Trials...keeping you current

ARIAD Announces Full Enrollment in Phase 3 Succeed Trial Evaluating Ridaforolimus in Patients with Metastatic Sarcomas
ARIAD Pharmaceuticals, 12/18/09

Phase I trial of motexafin gadolinium and doxorubicin in the treatment of advanced malignancies
Investigational New Drugs, 12/18/09

Prognostic Factors in Idiopathic Pulmonary Fibrosis
The American Journal of the Medical Sciences, 12/17/09

Today in M&A/Partnerships...keeping you current

Covidien Announces Definitive Agreement to Sell U.S. Radiopharmacies
Covidien, 12/18/09

MediciNova and Avigen Stockholders Approve Merger
Avigen, 12/18/09

GlaxoSmithKline and NanoBio announce OTC licensing agreement for cold sore treatment
GlaxoSmithKline, 12/18/09

Today in Research & Development...keeping you current

GlaxoSmithKline and NanoBio announce OTC licensing agreement for cold sore treatment
GlaxoSmithKline, 12/18/09

ARIAD Announces Full Enrollment in Phase 3 Succeed Trial Evaluating Ridaforolimus in Patients with Metastatic Sarcomas
ARIAD Pharmaceuticals, 12/18/09

CCHIT Appoints Officers
HealthDataManagement, 12/18/09

Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Send this Summary to a Colleague

Enter email address